Morgan Stanley analyst Simeon Gutman maintains Arhaus (NASDAQ:ARHS) with a Equal-Weight and raises the price target from $8 to $9.
U.S. FDA Defers Action On Filing For AT-GAA In Late-Onset Pompe Disease
FDA Issues Deferred Action Letter on AT-GAA Regulatory Filing Due to the Inability to Conduct Required Manufacturing Site Inspection Prior to the PDUFA Action Date
Company is Now Actively Engaged with the Agency to